Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice

Young Sik Chung, Shin Ichi Miyatake, Akiko Miyamoto, Yoshiharu Miyamoto, Takehiko Dohi, Nobuhiko Tanigawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cell-specific, replicating viruses are being developed as a new class of oncolytic agents. A novel approach to viral gene therapy with the use of replication-competent herpes simplex virus has been described; G92A is a replication-competent, multimutant oncolytic herpes simplex virus (HSV) that has been evaluated for anticancer effects and selectivity in the treatment of subcutaneous tumors. G92A replicates efficiently in albumin-producing tumor cell lines but not in non-albumin-producing tumor cell lines, whereas both types are equally susceptible to a non-tissue-specific recombinant HSV, hrR3. In this study, we analyzed the antitumoral efficacy of a single intrasplenic G92A or hrR3 injection in nude mice. In vivo, G92A replicated well in liver xenografts of human albumin-producing hepatoma cells (Hep3B) but not in liver xenografts of a non-albumin-producing malignant colon tumor cell line (HT29), whereas hrR3 replicated well in both tumor types. G92A effectively and selectively replicated throughout liver tumors without apparent hepatotoxicity and inhibited tumor growth, leading to a significantly increased survival time. By monitoring lacZ histochemical staining, we determined the oncolytic potential of recombinant HSV against liver tumors. Our results indicate that G92A warrants further investigation as a clinical therapy against malignant liver tumors.

Original languageEnglish (US)
Pages (from-to)793-798
Number of pages6
JournalInternational journal of oncology
Volume28
Issue number4
StatePublished - Apr 1 2006

Fingerprint

Simplexvirus
Nude Mice
Liver
Tumor Cell Line
Neoplasms
Heterografts
Albumins
Therapeutics
Oncolytic Viruses
Viral Genes
Genetic Therapy
Hepatocellular Carcinoma
Colon
Staining and Labeling
Viruses
Injections
Survival
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chung, Y. S., Miyatake, S. I., Miyamoto, A., Miyamoto, Y., Dohi, T., & Tanigawa, N. (2006). Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice. International journal of oncology, 28(4), 793-798.
Chung, Young Sik ; Miyatake, Shin Ichi ; Miyamoto, Akiko ; Miyamoto, Yoshiharu ; Dohi, Takehiko ; Tanigawa, Nobuhiko. / Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice. In: International journal of oncology. 2006 ; Vol. 28, No. 4. pp. 793-798.
@article{b5bdb2f2def249a395922105e1b49754,
title = "Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice",
abstract = "Cell-specific, replicating viruses are being developed as a new class of oncolytic agents. A novel approach to viral gene therapy with the use of replication-competent herpes simplex virus has been described; G92A is a replication-competent, multimutant oncolytic herpes simplex virus (HSV) that has been evaluated for anticancer effects and selectivity in the treatment of subcutaneous tumors. G92A replicates efficiently in albumin-producing tumor cell lines but not in non-albumin-producing tumor cell lines, whereas both types are equally susceptible to a non-tissue-specific recombinant HSV, hrR3. In this study, we analyzed the antitumoral efficacy of a single intrasplenic G92A or hrR3 injection in nude mice. In vivo, G92A replicated well in liver xenografts of human albumin-producing hepatoma cells (Hep3B) but not in liver xenografts of a non-albumin-producing malignant colon tumor cell line (HT29), whereas hrR3 replicated well in both tumor types. G92A effectively and selectively replicated throughout liver tumors without apparent hepatotoxicity and inhibited tumor growth, leading to a significantly increased survival time. By monitoring lacZ histochemical staining, we determined the oncolytic potential of recombinant HSV against liver tumors. Our results indicate that G92A warrants further investigation as a clinical therapy against malignant liver tumors.",
author = "Chung, {Young Sik} and Miyatake, {Shin Ichi} and Akiko Miyamoto and Yoshiharu Miyamoto and Takehiko Dohi and Nobuhiko Tanigawa",
year = "2006",
month = "4",
day = "1",
language = "English (US)",
volume = "28",
pages = "793--798",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

Chung, YS, Miyatake, SI, Miyamoto, A, Miyamoto, Y, Dohi, T & Tanigawa, N 2006, 'Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice', International journal of oncology, vol. 28, no. 4, pp. 793-798.

Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice. / Chung, Young Sik; Miyatake, Shin Ichi; Miyamoto, Akiko; Miyamoto, Yoshiharu; Dohi, Takehiko; Tanigawa, Nobuhiko.

In: International journal of oncology, Vol. 28, No. 4, 01.04.2006, p. 793-798.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice

AU - Chung, Young Sik

AU - Miyatake, Shin Ichi

AU - Miyamoto, Akiko

AU - Miyamoto, Yoshiharu

AU - Dohi, Takehiko

AU - Tanigawa, Nobuhiko

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Cell-specific, replicating viruses are being developed as a new class of oncolytic agents. A novel approach to viral gene therapy with the use of replication-competent herpes simplex virus has been described; G92A is a replication-competent, multimutant oncolytic herpes simplex virus (HSV) that has been evaluated for anticancer effects and selectivity in the treatment of subcutaneous tumors. G92A replicates efficiently in albumin-producing tumor cell lines but not in non-albumin-producing tumor cell lines, whereas both types are equally susceptible to a non-tissue-specific recombinant HSV, hrR3. In this study, we analyzed the antitumoral efficacy of a single intrasplenic G92A or hrR3 injection in nude mice. In vivo, G92A replicated well in liver xenografts of human albumin-producing hepatoma cells (Hep3B) but not in liver xenografts of a non-albumin-producing malignant colon tumor cell line (HT29), whereas hrR3 replicated well in both tumor types. G92A effectively and selectively replicated throughout liver tumors without apparent hepatotoxicity and inhibited tumor growth, leading to a significantly increased survival time. By monitoring lacZ histochemical staining, we determined the oncolytic potential of recombinant HSV against liver tumors. Our results indicate that G92A warrants further investigation as a clinical therapy against malignant liver tumors.

AB - Cell-specific, replicating viruses are being developed as a new class of oncolytic agents. A novel approach to viral gene therapy with the use of replication-competent herpes simplex virus has been described; G92A is a replication-competent, multimutant oncolytic herpes simplex virus (HSV) that has been evaluated for anticancer effects and selectivity in the treatment of subcutaneous tumors. G92A replicates efficiently in albumin-producing tumor cell lines but not in non-albumin-producing tumor cell lines, whereas both types are equally susceptible to a non-tissue-specific recombinant HSV, hrR3. In this study, we analyzed the antitumoral efficacy of a single intrasplenic G92A or hrR3 injection in nude mice. In vivo, G92A replicated well in liver xenografts of human albumin-producing hepatoma cells (Hep3B) but not in liver xenografts of a non-albumin-producing malignant colon tumor cell line (HT29), whereas hrR3 replicated well in both tumor types. G92A effectively and selectively replicated throughout liver tumors without apparent hepatotoxicity and inhibited tumor growth, leading to a significantly increased survival time. By monitoring lacZ histochemical staining, we determined the oncolytic potential of recombinant HSV against liver tumors. Our results indicate that G92A warrants further investigation as a clinical therapy against malignant liver tumors.

UR - http://www.scopus.com/inward/record.url?scp=33744719735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744719735&partnerID=8YFLogxK

M3 - Article

C2 - 16525626

AN - SCOPUS:33744719735

VL - 28

SP - 793

EP - 798

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -